staff shortages

Patients

*Disclaimer: The views and opinions expressed here are the author’s own and do not necessarily reflect those of pharmaphorum or its editorial staff.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.